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cancers according to plasma angiopoietin-2 levels
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Abstract
Background: Optimization of chemotherapy effectiveness in metastatic colorectal cancers (mCRC) is a major
endpoint to enhance the possibility of curative intent surgery. FOLFIRI3 has shown promising results as second-line
chemotherapy for mCRC patients previously exposed to oxaliplatin. The clinical efficacy of FOLFIRI3 was never
determined in association with bevacizumab in non-previously treated mCRC patients.
Methods: We conducted a phase II clinical trial to characterize the response rate and toxicity profile of
FOLFIRI3-bevacizumab as initial treatment for mCRC. Sixty-one patients enrolled in 3 investigation centers were
treated with FOLFIRI3-bevacizumab (median of 10 cycles) followed by a maintenance therapy combining
bevacizumab and capecitabine. Levels of plasma angiopoietin-2 (Ang-2) were measured by enzyme-linked
immunosorbent assay at baseline.
Results: Overall response rate (ORR) was 66.7% (8% of complete and 58% of partial responses). The disease control
rate was 91.7%. After a median time of follow-up of 46.7 months, 56 patients (92%) had progressed or died. The median
progression free survival (PFS) was 12.7 months (95% confidence interval (CI) 9.7-15.8 months). The median overall
survival (OS) was 24.5 months (95% CI: 10.6-38.3 months). Twenty-one patients underwent curative intent-surgery
including 4 patients with disease initially classified as unresectable. Most common grade III-IV toxicities were diarrhea
(15%), neutropenia (13%), asthenia (10%), and infections (4%). Hypertension-related medications needed to be
increased in 3 patients. In multivariate analysis, surgery of metastases and Ang-2 levels were the only independent
prognostic factors for PFS and OS. Indeed, baseline level of Ang-2 above 5 ng/mL was confirmed as an independent
prognostic factor for progression free survival (HR = 0.357; 95% CI: 0.168-0.76, p = 0.005) and overall survival
(HR = 0.226; 95% CI: 0.098-0.53, p = 0.0002).
Conclusions: As front-line therapy, FOLFIRI-3-bevacizumab is associated with an acceptable toxicity and induced
promising objective response rates. However, unfavorable clinical outcomes were observed in patients with high levels
of angiopoietin-2.
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Background
Recent advances in surgery of metastases, as well as the
widespread use of adjuvant chemotherapy, improved
the outcomes of colorectal cancer patients [1-3]. For
patients diagnosed with metastatic disease or relapsing
after oxaliplatin-based adjuvant therapy, optimization of
chemotherapy effectiveness is a major endpoint to en-
hance the possibility of curative intent surgery. For those
patients, CPT-11 (irinotecan)-containing chemotherapies
are an available option, particularly when combined with
biotherapies.
Irinotecan, a campthotecin analogue, inactivates topo-
isomerase I via its active metabolite SN38. In first-line
mCRC patients, the addition of irinotecan (180 mg/m2) to
LV5FU2 (FOLFIRI) conferred a significant survival advan-
tage over LV5FU2 alone (leucovorin (LV) 200 mg/m2 day
1, 5-fluorouracil (5FU) bolus 400 mg/m2 day 1 followed
by a 46 hours-5FU continuous infusion 2400 mg/m2) [4].
Similarly, the addition of irinotecan to bolus of fluoroura-
cil resulted in longer overall survival compared to fluoro-
uracil alone [5]. The clinical benefit of irinotecan was also
demonstrated in patients whose disease had progressed
after first-line 5FU [6,7].
Irinotecan, administered alone or in combination with
LV5FU2 (FOLFIRI), is also a recommended therapy for
second-line metastatic diseases in patients previously
exposed to oxaliplatin. In this setting, irinotecan as single
agent or in combination with LV5FU2 induces a 4%
objective response rate and a progression free survival of
2.5 months [8,9]. These results prompted many investigators
to examine new approaches to optimize irinotecan-based
chemotherapies.
Bifractionated CPT-11 with LV5FU2 (FOLFIRI3) was
identified as an effective therapy in patients previously
exposed to oxaliplatin-containing chemotherapies [10-12].
In FOLFIRI3 regimen, 100 mg/m2 of irinotecan are
delivered as a 60 minutes infusion before and at the end of
LV5FU2. In a phase II trial, FOLFIRI3 regimen was assessed
in patients previously treated with FOLFOX and achieved
an objective response rate of 23%. Furthermore, a stable
disease was observed in 37% of the patients and the
progression free survival was 4.2 months [10]. Bidard FC
et al. analyzed the clinical interest of several irinotecan-
based protocols delivered in the second-line setting for
patients previously included in the OPTIMOX 1 study.
These patients were treated by FOLFOX in the first-line
setting and were prospectively registered for subsequent
treatments. FOLFIRI3 chemotherapy was associated
with a significantly better objective tumor response rate
(17% compared to 8% with FOLFIRI) and an enhanced
progression free survival (3.7 months compared to
3 months with FOLFIRI) [11]. These results suggested
that bi-fractionated irinotecan might be a relevant option
for patients previously treated with oxaliplatin.
Then, this phase II clinical trial was designed to assess
the clinical efficacy and toxicity of FOLFIRI3 in combin-
ation with bevacizumab (FOLFIRI3-b), a Vascular Endo-
thelial Growth Factor-neutralizing monoclonal antibody
indicated for the first-line treatment of metastatic CRC
patients [13].
Although there are currently no biomarkers with proven
clinical interest to identify patients eligible to bevacizumab
and chemotherapy, a pilot study performed on 34 meta-
static colorectal cancer patients treated with chemother-
apy and bevacizumab showed that high levels of plasma
angiopoietin-2 predict a poor prognosis [14]. Therefore,
we decided to perform an ancillary study to further sub-
stantiate the prognostic value of baseline angiopoietin-2
plasma levels in patients treated with FOLFIRI3 and
bevacizumab.
Methods
Study design
The main objective of this single-arm phase II study was
to determine the objective response rate of FOLFIRI3-b
for patients undergoing first-line treatment of metastatic
colorectal cancer. Secondary objectives were the moni-
toring of side effects, the assessment of median progres-
sion free and overall survival and the characterization of
angiopoietin-2 prognostic value. Sixty-one patients were
enrolled in two general hospitals and a university hos-
pital. The study was conducted in accordance with the
Declaration of Helsinki, the International Conference on
Harmonization Guidelines for Good Clinical Practice.
Each patient gave written consent before entering the
study. The protocol was approved by the ethical commit-
tee CPP Est-II and registered on ClinicalTrials.gov (study
NCT00544011).
Eligibility
Patients with first-line mCRC and measurable lesions
were included. Previous adjuvant chemotherapy was
allowed provided that the last administration was given
at least 6 months before randomization. Other eligibility
criteria were: age 18 to 80 years, Eastern Cooperative
Oncology Group Performance Status 0, 1 or 2 and written
informed consent. Exclusion criteria included: previous
bevacizumab treatment; proteinuria exceeding 1 g/24 h;
coagulopathy; inadequate hematologic function (absolute
neutrophil count < 1.0 × 109/L, platelets < 100 × 109/L);
inadequate hepatic function (total bilirubin > 1.5× upper
limit of normal (ULN), serum transaminases > 2× ULN
in absence of liver metastases or > 5× ULN in presence
of liver metastases); inadequate renal function (clear-
ance of creatinine < 30 ml/min); major surgery <28 days
before inclusion; non-controlled cardiovascular disease;
non-controlled hypertension; active hemorrhagic event;
aspirin more than 325 mg/day treatment. As the main
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objective was to assess the tumor response rate, patients
amenable to curative intent surgery were included in the
study. Surgery of metastases was allowed after 6 cycles of
FOLFIRI3-b and the precise timing left at the discretion of
investigators.
Treatment
FOLFIRI3-bevacizumab regimen consisted of bevacizu-
mab 5 mg/kg day 1, irinotecan 100 mg/m2 day 1, LV
400 mg/m2 day 1 followed by a 46-h 5-FU continuous
infusion (2400 mg/m2), and irinotecan 100 mg/m2 at
day 3 [12]. Induction treatment was administrated every
2 weeks for a maximum of 12 cycles, until disease pro-
gression, unacceptable toxicities, surgical intervention,
or withdrawal of consent.
Maintenance treatment consisted of bevacizumab 7.5 mg/
kg intravenous infusion over 60 minutes, and capecita-
bine 1000 mg/m2 day 1 to 14, every 3 weeks until tumor
progression, unacceptable toxicity, or withdrawal of
consent.
Dose reductions were required for all grade 3 or 4
toxicities attributed to study medications. Bevacizumab
was not dose reduced but delayed or discontinued in
patients with grade 3 or 4 toxicities.
Safety and efficacy assessment
At baseline and before each cycle, clinical and biological
examinations were performed. Adverse events were eval-
uated continuously and graded according to National
Cancer Institute Common Toxicity Criteria (NCI CTC)
version 3. The response was defined according to Re-
sponse Evaluation Criteria In Solid Tumors (RECIST)
v1.0. Radiological response assessment was validated in
a blinded fashion by an independent radiologist. Tumor
responses were assessed every eight weeks by spiral
computed tomography. Resectability of metastases was
determined by IRFC-multidisciplinary gastrointestinal
oncology team before treatment initiation and when the
best response was achieved.
Plasma sample collection and analysis
Blood samples were drawn at baseline and immediately
processed for plasma and serum freezing at −80°C. Sam-
ples frozen more than 4 hours following venous blood
collection were not included in the analysis. Enzyme-
linked immunosorbent assays (ELISA) were used to
measure angiopoietin-2 in serum samples and VEGF-A
in plasma samples (RnD systems) according to the manu-
facturer’s instructions. Each sample was analyzed in
duplicate.
Statistical analysis
The primary endpoint of the trial was to determine the
objective response rate to the FOLFIRI3 sans espace
bevacizumab regimen in patients with first-line mCRC
cancers. The study was designed as an exploratory, pilot,
single-arm, multicenter, phase II study. A Simon two-stage
(optimal) design was used. At least 11 out of the first 21 pa-
tients needed to achieve an objective response in stage 1 for
recruitment to continue until a target of 45 fully evaluable
patients had been reached. Based on standards available
at the time of study design, we considered the standard
objective response rate (H0 hypothesis) achieved with
FOLFIRI and bevacizumab as 50%. Based on an α and β
error probabilities of 0.1 respectively, we considered that if
an objective response (complete and partial response) was
observed in at least 26 out of 45 patients with metastatic
colorectal cancers, the regimen would merit further evalu-
ation in prospective subsequent trials. Moreover, regarding
the high number of patients who underwent a curative
intent surgery, the cohort was extended to 61 patients to
include a total of 40 patients with non-resectable disease.
Survival data were computed according to Kaplan-Meier
method and analyses were performed on an intent-to-
treat population including all registered patients. Second-
ary endpoints were PFS, OS, toxicity profile, metastases
resection rate, and biologic analysis of possible predictive
factors of efficacy and toxicity. PFS was defined as the
time from study enrolment to the first documentation
of progressive disease (PD) or death from any cause.
Overall survival was defined as the time from study
enrolment to death from any cause.
Results
Baseline characteristics
Sixty-one patients were enrolled in the study between
October 2007 and July 2009. The median age of the
patients was 63.6 years (range, 38–81). Fifty-seven patients
(93%) had an Eastern Cooperative Oncology Group
Performance Status (ECOG PS) 0–1. Thirty-five patients
(57%) presented only one metastatic site and 7 patients
(12%) had 3 or more visceral sites involved by metastases.
Twenty-five patients (41%) had liver-limited metastases.
Twenty-two patients (36%) displayed metachronous
metastases at inclusion. Eighteen patients (30%) had
received prior adjuvant chemotherapy, including an
oxaliplatin-based chemotherapy for 15 patients (25% of
the whole cohort). Primary tumor was resected in 3 out
of the 39 synchronous metastatic patients. Two primary
tumor resections were performed before enrolment due
to a symptomatic disease and one resection was per-
formed after enrolment due to an occlusion (Table 1).
Administration of FOLFIRI3-bevacizumab
All patients accomplished at least one cycle of treatment.
Patients received a median of 10 cycles of induction
chemotherapy (range 2–14) and 40 patients completed
all planned cycles of FOLFIRI3-b. Twenty-one patients
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(34%) discontinued their induction treatment: 6 for
progression, 3 for treatment-related toxicities and 12 for
programmed metastasis surgery. The relative dose inten-
sity (calculated from FOLFIRI3-b initiation to the last
course of chemotherapy delivered before toxicity, disease
progression, surgery, or the planned 12th cycle of
FOLFIRI3-b) was 88% for Irinotecan, 85% for 5-FU, and
87% for bevacizumab. Median dose administered for
each cycle was 91% for irinotecan, 95% for 5-FU, and
100% for bevacizumab.
Safety
Toxicity analysis was performed in the intent-to-treat
population (61 patients, Table 2). Twenty patients (33%)
suffered ≥ grade III treatment-related side effects. One
patient (1.6%) died during induction regimen due to
treatment-related toxicity (colitis and sepsis). Moreover,
one patient with synchronous metastases exhibited a
colon cancer bleeding requiring surgery. Post-operative
recovery was achieved within 7 days and chemotherapy
was reintroduced at day 28 post-surgery. Most common
grade III-IV toxicities were diarrhea (15%), neutropenia
(13%), asthenia (10%), and infections (4%). Hypertension-
related medications needed to be increased in 3 patients.
Efficacy
Among the 60 assessable patients, ORR was 66.7% (95%
CI: 55–79) including 58.4% of partial responses and 8.3%
of complete responses (CR). Stable disease (SD) was
observed in 25% of patients conferring to this strategy a
disease control rate of 91.7%. An independent review of
the radiological responses was performed and showed only
one difference: one patient was considered to be in CR by
our investigators and in non-measurable SD by the
independent committee. However, later liver resection
confirmed histological CR.
After a median time of follow-up of 46.7 months (data
base up-dated in December 2012), 56 patients (92%) had
progressed. The median PFS was 12.72 months (95% CI:
9–16 months). So far, 42 patients (68.8%) have died and
median OS was 24.5 months (95% CI: 10.6-38.3 months).
Of note, none of the patient’s characteristics influenced
the clinical results achieved with FOLFIRI3-bevacizumab
treatment. Particularly, the ORR was 58.3% in patients
above 70 year-old compared to 68.8% for patients less
than 70 year old at the inclusion (p = 0.51). Moreover,
FOLFIRI3-bevacizumab was also effective in patients
treated with oxaliplatin-based adjuvant chemotherapy
(ORR of 60%, p = 0.54).
Table 1 Patient’s characteristics
FOLFIRI3-bevacizumab
(n = 61)
Demographic or clinical characteristics No. of patients %
Male 35 57
Age, years
Median 63.6
Range 38-81
ECOG performance status
0 25 41
1 32 52
2 4 7
Primary tumor type
Colon 38 62
Rectal 23 38
No. of sites involved by metastases
1 35 57
2 19 31
> = 3 7 12
Site of metastatic disease
Liver only 25 41
Liver + other 20 33
Other only 16 26
Prior adjuvant chemotherapy
All 18 30
Oxaliplatin-based 15 25
< 12 months 8 13
Synchronous tumors
Yes 39 64
No 22 36
Table 2 Grade 3 and 4 adverse events: NCI CTC v.3
Induction
chemotherapy
Maintenance
chemotherapy
(N = 61) (N = 41)
Adverse events No. of patients % No. of patients %
Nausea 1 2 0 -
Vomiting 1 2 0 -
Diarrhea 9 15 2 5
Mucositis 0 - 0 -
Fatigue 6 10 1 2
Platelet count decreased 0 - 0 -
Anemia 0 - 0 -
White blood cell decreased 3 5 0 -
Neutropenia 8 13 0 -
(2 grade IV)
Febrile neutropenia 1 2 0 -
Hypertension 3 5 1 2
Hemorrhage 1 2 0 -
Thromboembolic event 0 - 1* 2
Palmar-plantar syndrome 0 - 6 15
*One catheter related deep vein thrombosis.
Grade IV toxicity: the only grade IV toxicity observed was neutropenia.
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Surgery of metastases
Twenty-one patients (34%) underwent curative-intent sur-
gery of their metastases. A complete histological response
was observed in 5 patients. R0 resection was achieved in
twenty patients, while the resection status was considered
as R1 for one patient. Four of these patients were initially
considered as non-resectable, including one patient with 2
sites involved by metastases (lung and liver). Five patients
(24%) among the 21 patients who have undergone metas-
tasis surgery were still in complete remission at the time
of the last analysis. The median progression free survival
was 23.6 months (95% CI: 17.3-29.9 months) in patients
who underwent a surgery of their metastases compared
to 9.4 months (95% CI: 8.47-10.33 months) for patients
with non-resected metastases (Figure 1; p < 0.001). The
median overall survival was not reached in patients
who underwent a metastatic surgery, while median OS
was 18.33 months (95% CI: 15.15-21.5 months) in patients
with unresectable disease (p < 0.001).
Feasibility and efficacy of maintenance treatment by
capecitabine-bevacizumab
Twenty patients did not receive maintenance chemo-
therapy: 1 patient died during induction regimen, 11
patients displayed progressive diseases before capecitabine-
bevacizumab initiation, 8 patients underwent curative-
intent surgery and no further treatment was proposed.
Then, capecitabine-bevacizumab therapy was administered
to 40 eligible patients and one more patient, who refused
capecitabine, received only bevacizumab.
A total of 346 cycles and a median of 8.7 cycles was
administered (range 1–33) per patient at the time of
analysis. Median dose of capecitabine per cycle and per
patient was 83.4%.
The treatment was generally well tolerated. No grade IV
toxicity was recorded and 20% of patients experienced
grade III toxicities. Most frequent grade III toxicities were
hand-foot syndrome (15%), and diarrhea (5%). Bevacizu-
mab had to be stopped before capecitabine in only one
case due to catheter-related deep vein thrombosis. Overall,
maintenance treatment was discontinued for toxicity or
withdrawal of consent in 2 patients (5%). The median dur-
ation of disease control from first cycle of maintenance
therapy was 8 months (range, 1–38).
High levels of plasma angiopoietin-2 at baseline correlate
with poor clinical outcomes in patients treated with
FOLFIRI3-b
In 51 patients, plasma and serum were available at base-
line for analysis. Among angiogenic factors, angiopoietin-2
(Ang-2) was recently proposed in a cohort of 34 patients,
as a candidate biomarker for outcomes of mCRC patients
treated with bevacizumab-containing chemotherapy [14].
Then, we decided to monitor Ang-2 and VEGF-A levels in
this study. Seven patients included in this phase II clinical
trial had increased VEGF-A levels compared to normal
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Figure 1 Kaplan Meier curve for progression free survival of metastatic colorectal cancer patients treated by FOLFIRI3-bevacizumab in
the first line setting. The probability of progression free survival is reported in the 21 patients treated with FOLFIRI3-bevacizumab who
underwent a surgery of their metastases and in the 40 patients with unresectable disease.
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volunteers or stage II-III colorectal cancers. However,
we did not observe a significant negative influence of
increased VEGF-A levels on the ORR (83%), PFS
(10.7 months) or OS (20.6 months). A preliminary set of
experiments confirmed that Ang-2 levels remain below
5 ng/mL in all normal volunteers (n = 20) or stage II-III
colorectal cancers (n = 20), in line with the results of
Goede et al. [14]. Ang-2 plasma levels above 5 ng/mL at
baseline were observed in nine patients (17.3%) of our
cohort. ORR was 44% in patients with increased levels
of Ang-2, compared to 74.4% in patients with Ang-2
levels below 5 ng/mL. The median PFS was 7.7 months
(95% CI: 0–15.9 months) in patients with high Ang-2
levels compared with 13.6 months (95% CI: 10.1-
17.2 months) in patients with Ang-2 levels below 5 ng/mL
(Figure 2A). Furthermore, overall survival was significantly
better in patients with low levels of Ang-2 (median OS:
34.7 months; 95% CI: 19.8-49.7) than in patients with
high levels of Ang-2 (median OS: 7.7 months; 95% CI:
5–16.3 months; Figure 2B). In multivariate analysis,
surgery of metastases and Ang-2 levels were the only
independent prognostic factors for PFS and OS. In-
deed, a level of Ang-2 above 5 ng/mL was confirmed as
an independent prognostic factor for progression free
survival (HR = 0.357; 95% CI: 0.168-0.76, p = 0.005)
and overall survival (HR = 0.226; 95% CI: 0.098-0.53,
p = 0.0002). Altogether, these results confirm the clinical
interest of angiopoietin-2 monitoring to predict PFS and
OS in mCRC patients and suggest a decreased efficacy of
FOLFIRI3-b in these patients.
Discussion
Irinotecan inhibits DNA replication by interfering with
topoisomerase I. Topoisomerase enzymes display a heli-
case activity involved in DNA repair. Then, it might be
possible that topoisomerase blockage following DNA
damage could prevent DNA repair and enhance apoptosis
induced by chemotherapy. Indeed, preclinical evidence
suggested that the anti-proliferative activity of 5FU and iri-
notecan combination is schedule dependent [15-18]. In
line with the above hypothesis, several studies showed that
a delayed administration of irinotecan increases FOLFIRI
cytotoxicity. FOLFIRI2 regimen (irinotecan delivery at the
end of a modified LV5FU2 chemotherapy) in heavily
pretreated CRC patients induced promising objective
responses but also a limiting hematologic toxicity [19]. As
reported here and in previous studies, FOLFIRI3 has a
more appropriate toxicity profile [12]. In addition, bifrac-
tionated irinotecan combined to LV5FU2 (FOLFIRI3) was
shown to be active in mCRC resistant to FOLFIRI and has
been correlated to a longer PFS in second line treatment
of mCRC patients [10-12]. However, the clinical interest
of this regimen was never investigated in the first-line
setting, where the best chemotherapy to combine with
bevacizumab is still a matter of debate.
In a pivotal randomized clinical trial, bevacizumab
combination with IFL (weekly irinotecan plus bolus 5-
fluorouracile/leucovorin) improved both median PFS
and median OS in previously untreated mCRC patients.
Patients receiving both bevacizumab and IFL had a me-
dian PFS of 10.6 months and a median OS of 20.3 months,
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Figure 2 Kaplan Meier curves for progression free survival and overall survival of metastatic colorectal cancer patients treated by FOLFIRI3-
bevacizumab in the first line setting, according to the baseline level of angiopoietin-2. (A) The probability of progression free survival was reported
in patients with baseline angiopoietin-2 levels below 5 ng/mL or above 5 ng/mL. (B) The probability of overall survival is shown according to baseline
angiopoietin-2 levels. Patients with baseline angiopoietin-2 levels above 5 ng/mL displayed a significantly decreased OS (p = 0.0002).
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while median PFS and OS were 6.2 and 15.6 months
respectively for patients treated with IFL alone [13].
FOLFIRI and bevacizumab efficacy was primarily assessed
in retrospective studies. López R et al. reported a 50.5%
objective response rate, a 10.6 month median PFS and a
20.7 month median OS in first line treatment of mCRC
patients [20]. Seventy one percent of these patients had
liver metastases and 14% of them underwent curative-
intent surgery. In this study, adverse events were the cause
of treatment discontinuation for 8% of the patients com-
pared to 5% in our study. In a recently reported phase II
trial including 43 patients, FOLFIRI and bevacizumab
achieved a 65% response rate, a 12.8 months median PFS
and a median OS of 31.9 months [21]. Adverse events
were the cause of treatment discontinuation in 8 patients
and curative-intent surgery was performed in 4 patients
[21]. Of note, the addition of bevacizumab to FOLFOX
has shown similar results with a response rate of 52% and
a median PFS of 9.9 months [22].
The BICC-C study contributed to clarify the relative
interest of three different irinotecan-based chemotherapies
in the first line treatment of mCRC. The addition of oral
capecitabine to irinotecan (CapeIRI) induced an enhanced
level of toxicities. Furthermore, median overall survival
was significantly higher for patients treated with FOLFIRI-
bevacizumab (median OS of 28 months vs 19.2 months
for mIFL-treated patients) [23].
In the current study, we found that FOLFIRI3- bevaci-
zumab was a manageable option in first line metastatic
colorectal cancer patients. Indeed, side effects and toxic
deaths observed in our study are comparable to those
reported by other clinical trials. The ratio of adverse
Table 3 Review of the main clinical trials performed in first line metastatic colorectal cancer
Chemotherapy Liver
metastases
only (%)
One metastatic
site only (%)
ORR (%) mPFS
(months)
mOS
(months)
Ref Comments
Tournigand C et al. [9] FOLFIRI NR 56 56 8.5 21.5 J Clin Oncol 2004;
22(2):229–37.
Colluci G et al. [34] FOLFIRI 50 56 31 7 14 J Clin Oncol 2005;
23:4866–4875.
Labiancha R et al. [35] FOLFIRI NR NR 42 6 18 Annals of Oncology
2011; 22:1236–1242.
Koopman M
(CAIRO study) [36]
FOLFOX or
FOLFIRI
23 NR 41 7,8 17.4 Lancet 2007;
370:135–42.
Ducreux M
(FFCD2000-05) [37]
FOLFOX NR 52 58 7.6 16.2 Lancet Oncol 2011;
12:1032–44.
Chibaudel B
(OPTIMOX2 study) [25]
FOLFOX7 NR 42 59.6 8,6 23.8 J Clin Oncol 2009;
27:5727–5733.
Maintenance
arm
Maughan TS
(COIN study arm 1) [38]
FOLFOX 21 35 57 8,6 17.9 Lancet 2011;
377(9783):2103–2114.
Hurwitz H et al. [13] IFL + Bev NR 37 44.8 10.6 20.3 N Engl J Med 2004;
350:2335–42.
Fuchs CS
(BICC study) [23]
Folfiri-bev NR NR 57.9 11.2 28 J Clin Oncol 2007;
25:4779–4786.
SALTZ LB
(NO16966) [39]
FOLFOX + bev NR 43 9.4 21.3 J Clin Oncol. 2008;
26(12):2013–9.
Schmoll HJ
(Horizon study) [40]
FOLFOX + bev 22 45 47 10.3 22.3 J Clin Oncol 2012;
30:3588–3595.
Van Cutsem
(Crystal study) [41]
FOLFIRI cetux 21,5 NR 57,2 9.9 23.5 J Clin Oncol 2011;
29:2011–2019.
Kras wt only
Maughan TS
(COIN study arm 2) [38]
FOLFOX cetux 24 37 64 8.6 17 Lancet. 2011;
377(9783):2103–2114.
Kras wt only
Douillard JY
(Prime study) [42]
FOLFOX
pamitumumab
18 21 55 9.6 23.9 J Clin Oncol 2010;
28:4697–4705.
Kras wt only
Bokemeyer
(OPUS study) [43]
FOLFOX + cetux 30 44 58 8.3 22.8 Annals of Oncology
2011; 22:1535–1546.
Kras wt only
Masi G [44] FOLFOXIRI 34 55 60 9.8 23.4 J Natl Cancer Inst
2011;103:21–30.
Masi G [30] FOLFOXIRI beva 53 58 77 13.1 30.9 Lancet Oncol 2010;
11:845–52.
(NR: not reported).
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events leading to death was 1.6% in our study compared
to 2.6% and 2% in the pivotal study reported by Hurwitz
et al. and by the BEAT study respectively [13,24].
Moreover, the present trial confirms the feasibility of a
maintenance chemotherapy combining capecitabine and
bevacizumab following FOLFIRI3-b. Maintenance chemo-
therapy might be a convenient fashion to extent the period
of disease control while minimizing the cumulative side
effects [25-28]. Our results indicate that bevacizumab and
capecitabine maintenance chemotherapy is feasible after
FOLFIRI3-bevacizumab, since no grade IV toxicity oc-
curred and only two patients out of 41 exposed to this
strategy, discontinued capecitabine following side effects.
A second conclusion that can be drawn from the
current study is that survival achieved in patients treated
by FOLFIRI3-b is similar to those reported by previous
clinical trials (Table 3). The median PFS and OS observed
in patients with unresectable metastases were 9.4 months
(95% CI: 8.47-10.33 months) and 18.33 months (95% CI:
15.15-21.5 months) respectively. Of note, patients in-
cluded in the CONcePT trial achieved a median PFS of
12 months [27], while patients included in the MACRO
trial and treated with Xelox-bevacizumab followed by
bevacizumab alone as a maintenance therapy displayed a
median PFS of 9.7 months and a median OS of 20 months
[28]. Moreover, we cannot exclude a negative impact of
FOLFIRI3-b regimen on patient’s quality of life. Indeed
FOLFIRI3-b requires the administration of irinotecan
twice per cycle (before and at the end of continuous 5FU),
extending both length of hospitalization and healthcare
travel costs.
Nevertheless, a possible clinical interest of FOLFIRI3-b
might be the high level of tumor shrinkage observed in
our study. Indeed, the 66.7% ORR observed in the
FOLFIRI3-bevacizumab study may be considered for
patients with primary unresectable disease in whom
downsizing is mandatory to allow metastasis surgery.
The correlation established between the response rate
and the resection rate supports chemotherapy optimization
in mCRC patients who might potentially become candidate
for surgery [29]. The high ORR observed in our study
might reflect a favorable selection of patients as suggested
by the ratio of patients with only one site involved by
metastases (57%). A review indicating the ORR, mPFS and
mOS achieved in recent clinical trials according to the ra-
tio of patients with only one metastatic site is summarized
in Table 3. FOLFIRI3 and bevacizumab combination com-
pares favorably with other regimen.
Promising results have also recently been reported in
57 mCRC patients treated with FOLFOXIRI and bevacizu-
mab. 44 of these patients (77%) achieved a partial response
and 26% of them underwent a radical surgery of their me-
tastases. FOLFOXIRI-bevacizumab led to a median PFS
and an OS of 13.1 and 30.9 months [30]. Then, FOLFIRI3-
bevacizumab might be of particular interest in patients
previously treated with oxaliplatin-containing adjuvant
chemotherapy and not eligible to FOLFOX or FOLFOX-
IRI regimen, especially if the induction of a tumor
shrinkage is require to allow optimal resection of the
metastatic disease. Of note, an ORR of 60% was achieved
after FOLFIRI3-b treatment in patients exposed to
oxaliplatin.
Finally, our study confirmed the prognostic value of
plasma angiopoietin-2 levels in metastatic CRC. This re-
sult is of particular interest since most angiogenic related
biomarkers might be related to prognosis only when mon-
itored after treatment initiation. Here, a baseline Ang-2
level above 5 ng/mL was confirmed as an independent
prognostic factor for progression free survival (HR =
0.357; 95% CI: 0.168-0.76, p = 0.005) and overall survival
(HR = 0.226; 95% CI: 0.098-0.53, p = 0.0002).
To our knowledge, angiopoietin-2 monitoring was not
reported in randomized clinical trials, precluding any
conclusion regarding a potential predictive value of this
biomarker.
However, our results are in agreement with the previous
report of Goede et al., where high levels of angiopoietin-2
had a prognosis value and correlated with a decreased
survival in a cohort of 34 colorectal cancer patients
treated by chemotherapy and bevacizumab [14].
Several evidences support the direct role of angiopoietin-2
in cancer prognosis. First, angiopoietin-2 expression was
shown to be correlated with colorectal cancer stages and
progression [31]. In addition, angiopoietin-2 was identi-
fied as an independent prognosis biomarker in myeloid
leukemia and melanoma patients not treated with anti-
angiogenic therapies [32,33].
Conclusion
In conclusion, front-line therapy with FOLFIRI-3-
bevacizumab is associated with an acceptable toxicity.
A promising objective response rate was achieved, par-
ticularly in patients previously exposed to oxaliplatin.
However, unfavorable clinical outcomes were observed
in patients with high levels of angiopoietin-2.
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